Risk stratification and treatment strategy of pulmonary embolism

Current Opinion in Critical Care

Volumn 18, Issue 4, 2012, Pages 318-325

  Penaloza, Andrea ^a   Roy, Pierre Marie ^b   Kline, Jeffrey ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ D'ANGERS   (France)

^c CAROLINAS MEDICAL CENTER   (United States)

Author keywords

pulmonary embolism; risk stratification; treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BIOLOGICAL MARKER; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; IDRABIOTAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NATRIURETIC FACTOR; RIVAROXABAN; TROPONIN; WARFARIN;

BLEEDING; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MORTALITY; OUTPATIENT CARE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHOCK;

ACUTE DISEASE; ANTICOAGULANTS; BELGIUM; BIOLOGICAL MARKERS; HEMODYNAMICS; HUMANS; PROGNOSIS; PULMONARY EMBOLISM; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 84863829363     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835444bc     Document Type: Review

References (61)

1. Laporte S, Mismetti P, Decousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117:1711-1716.
2. Aujesky D, Jimenez D, Mor MK, et al. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation 2009; 119:962-968.
3. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30:1165-1171.
4. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23 Suppl 1):I4-I8.
5. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005; 20:496-501.
6. Gibson NS, Sohne M, Buller HR. Prognostic value of echocardiography and spiral computed tomography in patients with pulmonary embolism. Curr Opin Pulm Med 2005; 11:380-384.
7. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123:1788-1830.
8. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29:2276-2315.
9. Squizzato A, Galli M, Dentali F, Ageno W. Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review. Eur Respir J 2009; 33:1148-1155.
10. Wicki J, Perrier A, Perneger TV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84:548-552.
11. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172:1041-1046.
12. Uresandi F, Otero R, Cayuela A, et al. A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism. Arch Bronconeumol 2007; 43:617-622.
13. Jakobsson C, Jimenez D, Gomez V, et al. Validation of a clinical algorithm to identify low-risk patients with pulmonary embolism. J Thromb Haemost 2010; 8:1242-1247.
14. Aujesky D, Roy PM, Le Manach CP, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 2006; 27:476-481.
15. Jimenez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007; 132:24-30.
16. Donze J, Le Gal G, Fine MJ, et al. Prospective validation of the pulmonary embolism severity index. a clinical prognostic model for pulmonary embolism. Thromb Haemost 2008; 100:943-948.
17. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost 2010; 8:1509-1514.
18. Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170:1383-1389.
19. Righini M, Roy PM, Meyer G, et al. The simplified pulmonary embolism severity index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost 2011; 9:2115-2117.
20. Kline J, Miller DW. Risk stratification for acute pulmonary embolism. J Natl Compr Canc Netw. 2012; 9:800-810.
21. Kline J, Roy P, Than M, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE tool. Thromb Res. 2012 [Epub ahead of print].
22. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29:1569-1577.
23. Coutance G, Cauderlier E, Ehtisham J, Hamon M. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a metaanalysis. Crit Care 2011; 15:R103.
24. Lu MT, Cai T, Ersoy H, et al. Comparison of ECG-gated versus nongated CT ventricular measurements in thirty patients with acute pulmonary embolism. Int J Cardiovasc Imaging 2009; 25:101-107.
25. Kang DK, Thilo C, Schoepf UJ, et al. CT signs of right ventricular dysfunction: prognostic role in acute pulmonary embolism. JACC Cardiovasc Imaging 2011; 4:841-849.
26. Kang DK, Ramos-Duran L, Schoepf UJ, et al. Reproducibility of CT signs of right ventricular dysfunction in acute pulmonary embolism. AJR Am J Roentgenol 2010; 194:1500-1506.
27. Berghaus TM, Haeckel T, Behr W, et al. Central thromboembolism is a possible predictor of right heart dysfunction in normotensive patients with acute pulmonary embolism. Thromb Res 2010; 126:e201-e205.
28. Gandara E, Bose G, Erkens P, et al. Outcomes of saddle pulmonary embolism: a nested case-control study. J Thromb Haemost 2011; 9:867-869.
29. Aviram G, Steinvil A, Berliner S, et al. The association between the embolic load and atrial size in acute pulmonary embolism. J Thromb Haemost 2011; 9:293-299.
30. Pruszczyk P, Pacho R, Ciurzynski M, et al. Short term clinical outcome of acute saddle pulmonary embolism. Heart 2003; 89:335-336.
31. Agterof MJ, Schutgens RE, Verzijlbergen JF, et al. No firm association between N-terminal pro-brain natriuretic peptide and percentage of pulmonary vascular obstruction in patients with acute pulmonary embolism. Thromb Res 2011; 127:547-550.
32. Kline JA, Zeitouni R, Hernandez-Nino J, Rose GA. Size isnt everything. J Thromb Haemost 2008; 6:397-399.
33. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389.
34. Girard P, Sanchez O, Leroyer C, et al. Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance. Chest 2005; 128:1593-1600.
35. Jimenez D, Aujesky D, Diaz G, et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010; 181:983-991.
36. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178:425-430.
37. Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64:869-875.
38. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116:427-433.
39. Jimenez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136:974-982.
40. Moores L, Aujesky D, Jimenez D, et al. Pulmonary embolism severity index and troponin testing for the selection of low-risk patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2010; 8:517-522.
41. Jimenez D, Aujesky D, Moores L, et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011; 66:75-81.
42. Lankeit M, Friesen D, Aschoff J, et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31:1836-1844.
43. Lankeit M, Jimenez D, Kostrubiec M, et al. Predictive value of the highsensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124:2716-2724.
44. Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177:1018-1025.
45. Boscheri A, Wunderlich C, Langer M, et al. Correlation of heart-type fatty acidbinding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J 2010; 160:294-300.
46. Sanchez O, Trinquart L, Caille V, et al. Prognostic factors for pulmonary embolism: the PREP study, a prospective multicenter cohort study. Am J Respir Crit Care Med 2010; 181:168-173.
47. Chan CM, Woods CJ, Shorr AF. Comparing the pulmonary embolism severity index and the prognosis in pulmonary embolism scores as risk stratification tools. J Hosp Med 2011. doi: 10.1002/jhm.932. [Epub ahead of print]
48. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-2352.
49. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-2510.
50. Büller HR, Prins MH, Lensin AW, et al. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-1297.
51. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.
52. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8:722-729.
53. Buller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, noninferiority trial. Lancet 2012; 379:123-129.
54. Dong BR, Hao Q, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2009: CD 004437.
55. Lankeit M, Konstantinides S. Mortality risk assessment and the role of thrombolysis in pulmonary embolism. Crit Care Clin; 27:953-967, vii-viii.
56. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110:744-749.
57. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl):e419S-94S.
58. Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125:e82-e86.
59. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 2012; 163:33-8e1.
60. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, noninferiority trial. Lancet 2011; 378:41-48.
61. Stein PD, Goodman LR, Hull RD, et al. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost 2012; 18:20-26.